AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Hold” from Analysts

Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) have received an average rating of “Hold” from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $7.75.

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Wednesday, January 21st. Wall Street Zen raised AbCellera Biologics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th.

Hedge Funds Weigh In On AbCellera Biologics

A number of hedge funds have recently bought and sold shares of the business. Hsbc Holdings PLC raised its stake in AbCellera Biologics by 375.4% in the 4th quarter. Hsbc Holdings PLC now owns 117,031 shares of the company’s stock worth $401,000 after purchasing an additional 92,414 shares in the last quarter. Virtu Financial LLC bought a new position in shares of AbCellera Biologics during the fourth quarter worth approximately $619,000. Invesco Ltd. increased its holdings in shares of AbCellera Biologics by 27.9% during the fourth quarter. Invesco Ltd. now owns 54,603 shares of the company’s stock worth $187,000 after purchasing an additional 11,914 shares during the period. XTX Topco Ltd acquired a new stake in shares of AbCellera Biologics in the fourth quarter valued at approximately $1,242,000. Finally, nVerses Capital LLC bought a new stake in shares of AbCellera Biologics in the fourth quarter valued at approximately $121,000. 61.42% of the stock is owned by institutional investors.

AbCellera Biologics Price Performance

Shares of ABCL opened at $3.40 on Friday. The company’s 50-day moving average is $3.60 and its 200-day moving average is $4.13. The firm has a market capitalization of $1.03 billion, a PE ratio of -6.94 and a beta of 0.84. AbCellera Biologics has a fifty-two week low of $1.89 and a fifty-two week high of $6.51.

AbCellera Biologics (NASDAQ:ABCL) last announced its earnings results on Tuesday, February 24th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.15. The business had revenue of $44.85 million during the quarter, compared to the consensus estimate of $6.31 million. AbCellera Biologics had a negative net margin of 198.37% and a negative return on equity of 15.05%. Analysts predict that AbCellera Biologics will post -0.59 earnings per share for the current fiscal year.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.